Zentalis Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Basic Shares Outstanding (Weighted Average) of 71.33 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 71.33M shares, a 0.93% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 70.26M shares, a 1.97% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 71.66M shares, a 0.55% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 72.14M shares, a 1.45% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 71.87M shares, a 1.11% increase from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 71.08M shares, a 8.67% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 65.41M shares, a 23.75% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 52.86M shares, a 23.82% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 71.33M shares 10-Q · filed 2026-08-06 | 70.80M shares 10-Q · filed 2026-08-06 | 71.08M shares derived: average of 3 quarters · filed 2026-08-06 | 71.35M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 70.26M shares 10-Q · filed 2026-05-12 | 70.96M shares derived: average of 2 quarters · filed 2026-05-12 | 71.36M shares derived: average of 3 quarters · filed 2026-05-12 | 71.51M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 71.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 71.90M shares derived: average of 2 quarters · filed 2026-03-26 | 71.93M shares derived: average of 3 quarters · filed 2026-08-06 | 71.87M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 72.14M shares 10-Q · filed 2025-11-10 | 72.07M shares derived: average of 2 quarters · filed 2026-08-06 | 71.94M shares 10-Q · filed 2025-11-10 | 71.77M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 71.99M shares 10-Q · filed 2026-08-06 | 71.84M shares 10-Q · filed 2026-08-06 | 71.65M shares derived: average of 3 quarters · filed 2026-08-06 | 71.51M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 71.68M shares 10-Q · filed 2026-05-12 | 71.47M shares derived: average of 2 quarters · filed 2026-05-12 | 71.35M shares derived: average of 3 quarters · filed 2026-05-12 | 71.27M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 71.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 71.19M shares derived: average of 2 quarters · filed 2026-03-26 | 71.14M shares derived: average of 3 quarters · filed 2026-03-26 | 71.08M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 71.11M shares 10-Q · filed 2025-11-10 | 71.08M shares derived: average of 2 quarters · filed 2025-11-10 | 71.02M shares 10-Q · filed 2025-11-10 | 70.97M shares derived: average of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | 71.04M shares 10-Q · filed 2025-08-06 | 70.97M shares 10-Q · filed 2025-08-06 | 70.92M shares derived: average of 3 quarters · filed 2026-03-26 | 70.85M shares derived: average of 4 quarters · filed 2026-03-26 |
| 2024-03-31 | 70.90M shares 10-Q · filed 2025-05-14 | 70.87M shares derived: average of 2 quarters · filed 2026-03-26 | 70.78M shares derived: average of 3 quarters · filed 2026-03-26 | 68.28M shares derived: average of 4 quarters · filed 2026-03-26 |
| 2023-12-31 | 70.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 70.72M shares derived: average of 2 quarters · filed 2026-03-26 | 67.41M shares derived: average of 3 quarters · filed 2026-03-26 | 65.41M shares 10-K · filed 2026-03-26 |
| 2023-09-30 | 70.61M shares 10-Q · filed 2024-11-12 | 65.70M shares derived: average of 2 quarters · filed 2024-11-12 | 63.60M shares 10-Q · filed 2024-11-12 | 62.20M shares derived: average of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | 60.79M shares 10-Q · filed 2024-08-09 | 60.04M shares 10-Q · filed 2024-08-09 | 59.40M shares derived: average of 3 quarters · filed 2025-03-26 | 58.75M shares derived: average of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | 59.28M shares 10-Q · filed 2024-05-07 | 58.71M shares derived: average of 2 quarters · filed 2025-03-26 | 58.07M shares derived: average of 3 quarters · filed 2025-03-26 | 56.33M shares derived: average of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | 58.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 57.47M shares derived: average of 2 quarters · filed 2025-03-26 | 55.35M shares derived: average of 3 quarters · filed 2025-03-26 | 52.86M shares 10-K · filed 2025-03-26 |
| 2022-09-30 | 56.81M shares 10-Q · filed 2023-11-06 | 53.96M shares derived: average of 2 quarters · filed 2023-11-06 | 51.10M shares 10-Q · filed 2023-11-06 | 49.54M shares derived: average of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | 51.12M shares 10-Q · filed 2023-08-09 | 48.20M shares 10-Q · filed 2023-08-09 | 47.11M shares derived: average of 3 quarters · filed 2023-08-09 | 46.49M shares derived: average of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | 45.24M shares 10-Q · filed 2023-05-10 | 45.11M shares derived: average of 2 quarters · filed 2023-05-10 | 44.94M shares derived: average of 3 quarters · filed 2023-05-10 | 43.89M shares derived: average of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | 44.98M shares 10-K · filed 2022-02-24 | 44.79M shares derived: average of 2 quarters · filed 2022-11-09 | 43.44M shares derived: average of 3 quarters · filed 2022-11-09 | 42.69M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 44.61M shares 10-Q · filed 2022-11-09 | 42.67M shares derived: average of 2 quarters · filed 2022-11-09 | 41.92M shares 10-Q · filed 2022-11-09 | 41.41M shares derived: average of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 40.74M shares 10-Q · filed 2022-08-09 | 40.55M shares 10-Q · filed 2022-08-09 | 40.34M shares derived: average of 3 quarters · filed 2022-08-09 | 39.75M shares derived: average of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | 40.36M shares 10-Q · filed 2022-05-05 | 40.15M shares derived: average of 2 quarters · filed 2022-05-05 | 39.42M shares derived: average of 3 quarters · filed 2022-05-05 | 38.15M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | 39.94M shares 10-K · filed 2022-02-24 | 38.95M shares derived: average of 2 quarters · filed 2022-02-24 | 37.42M shares derived: average of 3 quarters · filed 2022-02-24 | 28.11M shares 10-K · filed 2023-03-01 |
| 2020-09-30 | 37.96M shares 10-K · filed 2022-02-24 | 36.16M shares derived: average of 2 quarters · filed 2022-02-24 | 24.14M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 34.35M shares 10-K · filed 2022-02-24 | 16.98M shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 5.60M shares 10-K · filed 2022-02-24 | |||
| 2019-12-31 | 5.60M shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |